Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

GSK Gains on Report of Aggressive Private Equity Valuation for Consumer Unit

Published 12/10/2021, 12:58
Updated 12/10/2021, 12:58
© Reuters.

By Dhirendra Tripathi

Investing.com – GlaxoSmithKline (LON:GSK) traded 2.5% higher in Tuesday’s premarket after a newswire report suggesting the spin off of its consumer healthcare unit will unlock more value than thought.

Bloomberg reported that private equity groups eyeing the split reckon the unit could be worth up to $54 billion.

GSK is under pressure from activist investors such as Elliott Management to improve shareholder returns. According to its plans for the spin-off, the parent company should receive approximately $11.2 billion in dividends from the consumer unit when it is separated. GSK will keep up to 20% of the new consumer healthcare company as a short-term financial investment, which it intends to monetize later.

GSK expects to deliver sales growth of more than 5% and adjusted operating profit growth of over 10% over the next five years.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.